Feb 26 (Reuters) - ARCA Biopharma Inc:
* ARCA BIOPHARMA REPORTS TOPLINE PHASE 2B RESULTS FOR GENETIC-AF CLINICAL TRIAL
* ARCA BIOPHARMA INC - ANTICIPATES MEETING WITH U.S. FDA IN Q2 OF 2018 TO REVIEW PHASE 2 DATA AND PHASE 3 DEVELOPMENT PLAN
* ARCA BIOPHARMA INC - GENCARO DEMONSTRATES COMPARABLE EFFICACY TO ACTIVE CONTROL AND TREND FOR POTENTIAL GENCARO SUPERIORITY IN US PATIENT COHORT
* ARCA BIOPHARMA INC - SAFETY DATA INDICATED THAT GENCARO WAS GENERALLY SAFE AND WELL-TOLERATED IN AF/HEART FAILURE POPULATION
* ARCA BIOPHARMA INC - THREE PATIENTS DIED IN LONG-TERM TREATMENT EXTENSION PERIOD AFTER RECEIVING GENCARO FOR MORE THAN A YEAR
* ARCA BIOPHARMA INC - ENDED 2017 WITH CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALING $11.8 MILLION
* ARCA BIOPHARMA - BELIEVES FUNDS, WITH NET PROCEEDS OF ABOUT $3.4 MILLION RAISED IN JAN WILL BE SUFFICIENT TO FUND OPERATIONS THROUGH END OF 2018 Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.